54 related articles for article (PubMed ID: 35163398)
21. Identification of Arp2/3 Complex Subunits as Prognostic Biomarkers for Hepatocellular Carcinoma.
Huang S; Li D; Zhuang L; Sun L; Wu J
Front Mol Biosci; 2021; 8():690151. PubMed ID: 34307456
[TBL] [Abstract][Full Text] [Related]
22. Defective Neutrophil Transendothelial Migration and Lateral Motility in ARPC1B Deficiency Under Flow Conditions.
Kempers L; Sprenkeler EGG; van Steen ACI; van Buul JD; Kuijpers TW
Front Immunol; 2021; 12():678030. PubMed ID: 34135903
[TBL] [Abstract][Full Text] [Related]
23. Clinical impact of combined PTEN and ERG rearrangements in localized prostate cancer.
Fragkoulis C; Glykas I; Dellis A; Ntoumas K; Papatsoris A
Arch Ital Urol Androl; 2021 Mar; 93(1):84-85. PubMed ID: 33754616
[TBL] [Abstract][Full Text] [Related]
24. Cancer Statistics, 2021.
Siegel RL; Miller KD; Fuchs HE; Jemal A
CA Cancer J Clin; 2021 Jan; 71(1):7-33. PubMed ID: 33433946
[TBL] [Abstract][Full Text] [Related]
25. Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions.
Chalmers ZR; Burns MC; Ebot EM; Frampton GM; Ross JS; Hussain MHA; Abdulkadir SA
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):558-566. PubMed ID: 33420417
[TBL] [Abstract][Full Text] [Related]
26. Dual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer.
Ton AT; Singh K; Morin H; Ban F; Leblanc E; Lee J; Lallous N; Cherkasov A
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167327
[TBL] [Abstract][Full Text] [Related]
27. Loss of ARPC1B impairs cytotoxic T lymphocyte maintenance and cytolytic activity.
Randzavola LO; Strege K; Juzans M; Asano Y; Stinchcombe JC; Gawden-Bone CM; Seaman MN; Kuijpers TW; Griffiths GM
J Clin Invest; 2019 Dec; 129(12):5600-5614. PubMed ID: 31710310
[TBL] [Abstract][Full Text] [Related]
28. Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and ETV4 on whole-mount radical prostatectomy tissue.
Lu Z; Williamson SR; Carskadon S; Arachchige PD; Dhamdhere G; Schultz DS; Stricker H; Peabody JO; Jeong W; Chitale DA; Bismar TA; Rogers CG; Menon M; Gupta NS; Palanisamy N
Prostate; 2020 Jan; 80(1):38-50. PubMed ID: 31584209
[TBL] [Abstract][Full Text] [Related]
29. ARPC4 promotes bladder cancer cell invasion and is associated with lymph node metastasis.
Xu N; Qu GY; Wu YP; Lin YZ; Chen DN; Li XD; Chen SH; Huang JB; Zheng QS; Xue XY; Wei Y
J Cell Biochem; 2020 Jan; 121(1):231-243. PubMed ID: 31190401
[TBL] [Abstract][Full Text] [Related]
30. PTEN Loss in a Prostate Cancer Cohort From Jordan.
Al Bashir S; Alzoubi A; Alfaqih MA; Kheirallah K; Smairat A; Haddad H; Al-Dwairy A; Fawwaz BAB; Alzoubi M; Trpkov K
Appl Immunohistochem Mol Morphol; 2020; 28(5):389-394. PubMed ID: 30614821
[TBL] [Abstract][Full Text] [Related]
31. Short interfering RNA-mediated silencing of actin-related protein 2/3 complex subunit 4 inhibits the migration of SW620 human colorectal cancer cells.
Su X; Wang S; Huo Y; Yang C
Oncol Lett; 2018 Mar; 15(3):2847-2854. PubMed ID: 29435011
[TBL] [Abstract][Full Text] [Related]
32. The Actin Cytoskeleton and Actin-Based Motility.
Svitkina T
Cold Spring Harb Perspect Biol; 2018 Jan; 10(1):. PubMed ID: 29295889
[TBL] [Abstract][Full Text] [Related]
33. The expression of AURKA is androgen regulated in castration-resistant prostate cancer.
Kivinummi K; Urbanucci A; Leinonen K; Tammela TLJ; Annala M; Isaacs WB; Bova GS; Nykter M; Visakorpi T
Sci Rep; 2017 Dec; 7(1):17978. PubMed ID: 29269934
[TBL] [Abstract][Full Text] [Related]
34. Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy.
Lahdensuo K; Erickson A; Saarinen I; Seikkula H; Lundin J; Lundin M; Nordling S; Bützow A; Vasarainen H; Boström PJ; Taimen P; Rannikko A; Mirtti T
Mod Pathol; 2016 Dec; 29(12):1565-1574. PubMed ID: 27562498
[TBL] [Abstract][Full Text] [Related]
35. SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development.
Huang KC; Bégin LR; Palanisamy N; Donnelly B; Bismar TA
Urol Oncol; 2016 May; 34(5):235.e1-10. PubMed ID: 26725250
[TBL] [Abstract][Full Text] [Related]
36. ERG expression in prostate cancer: biological relevance and clinical implication.
Abou-Ouf H; Zhao L; Bismar TA
J Cancer Res Clin Oncol; 2016 Aug; 142(8):1781-93. PubMed ID: 26711283
[TBL] [Abstract][Full Text] [Related]
37. The role of actin-binding proteins in the control of endothelial barrier integrity.
García-Ponce A; Citalán-Madrid AF; Velázquez-Avila M; Vargas-Robles H; Schnoor M
Thromb Haemost; 2015 Jan; 113(1):20-36. PubMed ID: 25183310
[TBL] [Abstract][Full Text] [Related]
38. Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition.
Han S; Brenner JC; Sabolch A; Jackson W; Speers C; Wilder-Romans K; Knudsen KE; Lawrence TS; Chinnaiyan AM; Feng FY
Neoplasia; 2013 Oct; 15(10):1207-17. PubMed ID: 24204199
[TBL] [Abstract][Full Text] [Related]
39. Expression of the Arp2/3 complex in human gliomas and its role in the migration and invasion of glioma cells.
Liu Z; Yang X; Chen C; Liu B; Ren B; Wang L; Zhao K; Yu S; Ming H
Oncol Rep; 2013 Nov; 30(5):2127-36. PubMed ID: 23969835
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
